Evaluation of Ureteral Jets on Cystoscopy
Information source: Cleveland Clinic Florida
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Injury of Ureter
Intervention: Normal saline (Drug); Phenazopyridine (Drug); Dextrose 10% (Drug); Sodium Fluorescein (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Cleveland Clinic Florida Official(s) and/or principal investigator(s): Guillermo Davila, MD, Study Chair, Affiliation: Cleveland Clinic Florida Alexandriah Alas, MD, Study Director, Affiliation: Cleveland Clinic Florida Luis M Espaillat, MD, Principal Investigator, Affiliation: Cleveland Clinic Florida
Overall contact: Sharon Lew, Phone: 954-659-5000, Email: lews2@ccf.org
Summary
This study evaluates 4 different methods to aid surgeons visualize ureteral jets on
cystoscopy.
Clinical Details
Official title: Evaluation of Ureteral Jets on Cystoscopy: A Randomized Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
Primary outcome: Ureteral Jet Visibility
Secondary outcome: Surgeon Satisfaction
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- adult
- undergoing a cystoscopy or as part of their planned procedure
Exclusion Criteria:
- Chronic kidney disease
- known prior surgical removal of kidney or ureteral obstruction
- Current ureteral stent placed
- Allergy to any of the interventions
Locations and Contacts
Sharon Lew, Phone: 954-659-5000, Email: lews2@ccf.org
Cleveland Clinic Florida, Weston, Florida 33331, United States; Recruiting Luis Espaillat, MD, Phone: 954-659-5559, Email: espaill2@ccf.org
Additional Information
Starting date: February 2015
Last updated: June 30, 2015
|